Pro PSA: A "pro cancer" form of PSA?

Medical Hypotheses

Volumn 64, Issue 1, 2005, Pages 92-95

  Peyromaure, Michaël ^a   Fulla, Yvonne ^a   Debré, Bernard ^a   Dinh Xuan, Anh Tuan ^a  

^a 75014 P ^*  (France)

Author keywords

[No Author keywords available]

Indexed keywords

ISOPROTEIN; PRO PROSTATE SPECIFIC ANTIGEN; PROSTATE SPECIFIC ANTIGEN; TUMOR MARKER; UNCLASSIFIED DRUG;

ANTIGEN FUNCTION; CELL SECRETION; DISEASE ASSOCIATION; DISEASE MARKER; HUMAN; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; PROTEIN FUNCTION; REVIEW; TUMOR BIOPSY;

EID: 7944220763     PISSN: 03069877     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mehy.2004.06.006     Document Type: Article

References (13)

1. S.P. Balk, Y.J. Ko, and G.J. Bubley Biology of prostate-specific antigen J. Clin. Oncol. 21 2 2003 383 391
2. S.D. Mikolajczyk, L.S. Grauer, and L.S. Millar A precursor form of PSA (pPSA) is a component of the free PSA in prostate cancer serum Urology 50 5 1997 710 714
3. J. Peter, C. Unverzagt, T.N. Krogh, O. Vorm, and W. Hoesel Identification of precursor forms of free prostate-specific antigen in serum of prostate cancer patients by immunosorption and mass spectrometry Cancer Res. 61 3 2001 957 962
4. S.D. Mikolajczyk, and H.G. Rittenhouse Pro PSA: a more cancer specific form of prostate specific antigen for the early detection of prostate cancer Keio J. Med. 52 2 2003 86 91
5. W.J. Catalona, A.W. Partin, and K.M. Slawin Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial JAMA 279 19 1998 1542 1547
6. W.J. Catalona, D.S. Smith, and D.K. Ornstein Prostate cancer detection in men with serum PSA concentrations of 2.6-4.0 ng/mL and benign prostate examination. Enhancement of specificity with free PSA measurements JAMA 277 18 1997 1452 1455
7. S.D. Mikolajczyk, L.S. Millar, and T.J. Wang A precursor form of prostate-specific antigen is more highly elevated in prostate cancer compared with benign transition zone prostate tissue Cancer Res. 60 3 2000 756 759
8. S.D. Mikolajczyk, K.M. Marker, and L.S. Millar A truncated precursor form of prostate-specific antigen is a more specific serum marker of prostate cancer Cancer Res. 61 18 2001 6958 6963
9. L.J. Sokoll, D.W. Chan, and S.D. Mikolajczyk Proenzyme PSA for the early detection of prostate cancer in the 2.5-4.0 ng/ml total PSA range: preliminary analysis Urology 61 2 2003 274 276
10. M.A. Khan, A.W. Partin, and H.G. Rittenhouse Evaluation of proprostate specific antigen for early detection of prostate cancer in men with a total prostate specific antigen range of 4.0 to 10.0 ng/ml J. Urol. 170 3 2003 723 726
11. W.J. Catalona, G. Bartsch, and H.G. Rittenhouse Serum pro prostate specific antigen improves cancer detection compared to free and complexed prostate specific antigen in men with prostate specific antigen 2 to 4 ng/ml J. Urol. 170 6 Pt 1 2003 2181 2185
12. S.D. Mikolajczyk, L.S. Millar, and T.J. Wang BPSA, a specific molecular form of free prostate-specific antigen, is found predominantly in the transition zone of patients with nodular benign prostatic hyperplasia Urology 55 1 2000 41 45
13. M. Han, A.W. Partin, C.R. Pound, J.I. Epstein, and P.C. Walsh Long-term biochemical disease-free and cancer-specific survival following anatomic radical retropubic prostatectomy. The 15-year Johns Hopkins experience Urol. Clin. North Am. 28 3 2001 555 565